Nuvalent to Participate in the UBS 2025 Virtual Oncology Day
Nuvalent (Nasdaq: NUVL), a clinical-stage biopharmaceutical company developing targeted cancer therapies, has announced its participation in the upcoming UBS 2025 Virtual Oncology Day. The company's CEO James Porter, Ph.D., and CFO Alexandra Balcom will engage in a fireside chat on October 1, 2025, at 3:30 p.m. ET.
Investors can access the live webcast through Nuvalent's website investor section, where it will remain available for 30 days after the presentation.
Nuvalent (Nasdaq: NUVL), azienda biofarmaceutica in fase clinica che sviluppa terapie mirate contro il cancro, ha annunciato la sua partecipazione al prossimo UBS 2025 Virtual Oncology Day. Il CEO James Porter, Ph.D. e la CFO Alexandra Balcom interverranno in un colloquio informale il 1 ottobre 2025 alle 15:30 ET. Gli investitori possono accedere al webcast in diretta tramite la sezione investitori del sito di Nuvalent, dove resterà disponibile per 30 giorni dopo la presentazione.
Nuvalent (Nasdaq: NUVL), una empresa biofarmacéutica en fase clínica que desarrolla terapias focalizadas contra el cáncer, ha anunciado su participación en el próximo UBS 2025 Virtual Oncology Day. El CEO James Porter, Ph.D. y la CFO Alexandra Balcom participarán en una charla junto al fuego el 1 de octubre de 2025 a las 3:30 p.m. ET. Los inversores pueden acceder al webcast en directo a través de la sección de inversores del sitio web de Nuvalent, y estará disponible durante 30 días tras la presentación.
Nuvalent (Nasdaq: NUVL)은(는) 표적 항암 치료를 개발하는 임상 단계 바이오제약 회사로서 다가오는 UBS 2025 Virtual Oncology Day에 참여한다고 발표했습니다. 최고경영자 James Porter 박사와 최고재무책임자 Alexandra Balcom은 2025년 10월 1일 동부 표준시 15:30에 파이어사이드 대담에 참여합니다. 투자자들은 Nuvalent 웹사이트의 투자자 섹션을 통해 라이브 웨비크에 접속할 수 있으며 발표 후 30일간 이용할 수 있습니다.
Nuvalent (Nasdaq: NUVL), une société biopharmaceutique clinique développant des thérapies ciblées contre le cancer, a annoncé sa participation au prochain UBS 2025 Virtual Oncology Day. Le PDG James Porter, Ph.D. et la directrice financière Alexandra Balcom prendront part à un fireside chat le 1 octobre 2025 à 15h30 HE. Les investisseurs peuvent accéder au webcast en direct via la section investisseurs du site de Nuvalent, qui restera disponible 30 jours après la présentation.
Nuvalent (Nasdaq: NUVL), ein klinisch entwickelndes Biopharmaunternehmen, das zielgerichtete Krebstherapien entwickelt, hat seine Teilnahme am bevorstehenden UBS 2025 Virtual Oncology Day bekannt gegeben. Der CEO James Porter, Ph.D. und der CFO Alexandra Balcom werden an einem Fireside-Chat am 1. Oktober 2025 um 15:30 Uhr ET teilnehmen. Investoren können den Live-Webcast über den Investorenbereich der Nuvalent-Website abrufen; er wird 30 Tage nach der Präsentation verfügbar bleiben.
Nuvalent (شركة ناسداك: NUVL)، وهي شركة أدوية حيوية في طور التجربة السريرية تطور علاجات سرطان مستهدفة، أعلنت عن مشاركتها في يوم الأورام الافتراضي UBS 2025 القادم. سيشارك الرئيس التنفيذي جيمس بورتر، دكتوراه والمدير المالي ألكسندرا بالكم في دردشة بجانب الموقد في 1 أكتوبر 2025، الساعة 3:30 مساءً بتوقيت شرق الولايات المتحدة. يمكن للمستثمرين الوصول إلى البث المباشر عبر قسم المستثمرين على موقع Nuvalent الإلكتروني، وسيظل متاحًا لمدة 30 يومًا بعد العرض.
Nuvalent (纳斯达克代码：NUVL)，一家处于临床阶段的生物制药公司，正在开发针对性的癌症治疗方法，宣布将参加即将举行的 UBS 2025 虚拟肿瘤日。公司首席执行官 James Porter 博士 和首席财务官 Alexandra Balcom 将于 2025 年 10 月 1 日，东部时间下午 3:30 进行炉边对谈（fireside chat）。投资者可以通过 Nuvalent 网站的投资者栏目访问现场网络广播，演示结束后将持续提供 30 天。
- None.
- None.
A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation.
About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-participate-in-the-ubs-2025-virtual-oncology-day-302565104.html
SOURCE Nuvalent, Inc.
FAQ
When is Nuvalent (NUVL) presenting at the UBS 2025 Virtual Oncology Day?
Who will represent Nuvalent at the UBS 2025 Virtual Oncology Day?
How can investors access Nuvalent's UBS Oncology Day presentation?
What type of company is Nuvalent (NUVL)?
